Physician profile
Amanda Johns
NPI 1679035091
$4,821.42
in general payments reported to CMS, 2019-2025
21 companies · $962 in 2025
The $962 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $493 · 2022: $905 · 2023: $723 · 2024: $1,738 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,225 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,224.70 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,558.47 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $567.44 | 2023-2025 | |
| Genzyme Corporation | $500.21 | 2021-2025 | |
| Incyte Corporation | $309.11 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $281.36 | 2024-2025 | Sotyktu |
| Janssen Biotech, INC. | $279.10 | 2024 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $211.17 | 2024-2025 | Dupixent, Libtayo |
| Ucb, INC. | $190.69 | 2025 | Bimzelx |
| Pfizer INC. | $184.50 | 2021-2025 | |
| Stemline Therapeutics INC. | $122.89 | 2021 | |
| Amgen INC. | $92.40 | 2022-2024 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.84 | 2023-2024 | Spevigo |
| Galderma Laboratories, L.P. | $81.89 | 2024-2025 | Nemluvio |
| Arcutis Biotherapeutics, INC. | $81.77 | 2024-2025 | Zoryve |
| Leo Pharma INC. | $75.04 | 2023-2024 | Adbry |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $62.69 | 2022-2024 | Winlevi |
| Lilly USA, LLC | $56.31 | 2022-2024 | Taltz, Olumiant |
| Krystal Biotech INC | $23.92 | 2024 | Vyjuvek |
| Kyowa Kirin, INC. | $23.18 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.07 | 2024 | Cabtreo |
| Almirall LLC | $15.37 | 2024 | Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Johns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.